Association between high-sensitivity troponin T, left ventricular hypertrophy, and myocardial performance index

Herz ◽  
2015 ◽  
Vol 40 (7) ◽  
pp. 1004-1010 ◽  
Author(s):  
Onur Kaypakli ◽  
Mustafa Gür ◽  
Mehmet Yavuz Gözükara ◽  
Hakan Uçar ◽  
Ali Kivrak ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Performance Index ◽  
Ventricular Hypertrophy ◽  
Troponin T ◽  
High Sensitivity ◽  
Left Ventricular ◽  
Myocardial Performance Index ◽  
Myocardial Performance ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T

scholarly journals Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR

2020 ◽  
Author(s):  
Hatim Seoudy ◽  
Moritz Lambers ◽  
Vincent Winkler ◽  
Linnea Dudlik ◽  
Sandra Freitag-Wolf ◽  
...  
Keyword(s):  
Troponin T ◽  
High Sensitivity ◽  
Left Ventricular ◽  
Adverse Outcomes ◽  
Chronic Obstructive ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T ◽  
Long Term Mortality

Abstract Background Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during follow-up after successful TAVR. We evaluated the long-term implications of elevated hs-TnT levels found at 1-year post-TAVR. Methods and results The study included 349 patients who underwent TAVR for severe AS from 2010–2019 and for whom 1-year hs-TnT levels were available. Any required percutaneous coronary interventions were performed > 1 week before TAVR. The primary endpoint was survival time starting at 1-year post-TAVR. Optimal hs-TnT cutoff for stratifying risk, identified by ROC analysis, was 39.4 pg/mL. 292 patients had hs-TnT < 39.4 pg/mL (median 18.3 pg/mL) and 57 had hs-TnT ≥ 39.4 pg/mL (median 51.2 pg/mL). The high hs-TnT group had a higher median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, greater left ventricular (LV) mass, higher prevalence of severe diastolic dysfunction, LV ejection fraction < 35%, severe renal dysfunction, and more men compared with the low hs-TnT group. All-cause mortality during follow-up after TAVR was significantly higher among patients who had hs-TnT ≥ 39.4 pg/mL compared with those who did not (mortality rate at 2 years post-TAVR: 12.3% vs. 4.1%, p = 0.010). Multivariate analysis identified 1-year hs-TnT ≥ 39.4 pg/mL (hazard ratio 2.93, 95% CI 1.91–4.49, p < 0.001), NT-proBNP level > 300 pg/mL, male sex, an eGFR < 60 mL/min/1.73 m2 and chronic obstructive pulmonary disease as independent risk factors for long-term mortality after TAVR. Conclusions Elevated hs-TnT concentrations at 1-year after TAVR were associated with a higher long-term mortality. Graphic abstract

Sign in / Sign up

Export Citation Format

Share Document